Poll

Hyperpigmented Axillae in an Obese Man

What disorders can give rise to pigmentary changes like this in an obese young man?

Hyperpigmentation is seen on the axillae of an obese 27-year-old man. The pigmentary changes are asymptomatic and have been present for several years.

Such hyperpigmentation is associated with which of the following disorders?

A. Diabetes
B. Corticosteroid excess
C. Pineal tumors
D. Genetic variants
E. All of the above
A. Diabetes
B. Corticosteroid excess
C. Pineal tumors
D. Genetic variants
E. All of the above
Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Related Content
Jörn M. Schattenberg, MD | Credit: LinkedIn
December 15th 2024

Study Highlights Real-World Mortality Rates, Factors Increasing Mortality Risk in MASH

Patrick Campbell
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia | Image Credit: US Food and Drug Administration
Published: December 13th 2024 | Updated: December 13th 2024

FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia

Connor Iapoce
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
A Pillared Approach: A Suite of THerapies for a Spectrum of Metabolic Disease
December 6th 2024

A Pillared Approach: A Suite of Therapies for a Spectrum of Metabolic Disease

Patrick Campbell
Stock image of body weight scale. | Credit: iStock
December 4th 2024

SURMOUNT-5: Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.